Translating Atopic Dermatitis

Slides:



Advertisements
Similar presentations
Eucrisa™ - Crisaborole
Advertisements

MOnoclonal antibodies and potential applications in migraine
Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape  Mark Boguniewicz, MD, Luz Fonacier, MD, Emma Guttman-Yassky,
Major Depressive Disorder: Latest Clinical Update
Clinical Trials in IBD.
The Role of Anticholinergic Therapy in Moderate to Severe Asthma
Essential Updates in Atopic Dermatitis:
Progression After Cancer Immunotherapy in Advanced NSCLC
The HCV Revolution: Are You and Your Practice Ready?
Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.
Seasonal Allergic Rhinitis
Updates on Outcomes for Novel T2D Therapies
PCP Perspectives Clinical Considerations in Hyperkalemia
Atopic Dermatitis Treatment Landscape
Updates in Management of Atopic Dermatitis From Real Patient Cases
Atopic Dermatitis Treatment Landscape
Program Goals. Program Goals What is Atopic Dermatitis?
What Has Been Tried and What Is True?
Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis  Lawrence F. Eichenfield, MD, Robert S. Call,
Therapeutic Strategies in the Management of Mild-to-Moderate Atopic Dermatitis.
Addressing Disease Burden in Asthma
Expert Tips for Tackling Atopic Dermatitis in Pediatric Practice
Managing CINV and Cachexia
Program Introduction. Monoclonal Antibodies and Immunogenicity: Relevance to Clinical Practice?
Managing gBRCA-Positive Metastatic Breast Cancer
Next-Gen Psoriasis Therapies:
PCSK9 Inhibitors and Cardiovascular Outcomes
A Better Solution For Cancer Patients With VTE?
Atopic Dermatitis. Introduction to a Clinical Course On New Developments In Atopic Dermatitis.
Emerging Atopic Dermatitis Treatments:
Tackling Atopic Dermatitis
Ask the Experts.
Current and Future Perspectives on Migraine Prevention Therapy
Personalized Therapy in Relapsed or Refractory CLL
Use of Combination of Saxagliptin/ Dapagliflozin in Patients With Poorly Controlled Diabetes on Metformin.
New Data on Emerging Treatments for Psoriasis
Improving Outcomes in Psoriatic Arthritis
The Evolving Treatment Landscape in Atopic Dermatitis
Current and Emerging Strategies for Management of Moderate-to-Severe Atopic Dermatitis.
Providing Hope and Opportunity
Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.
Getting to Grips With the Science of CGRP and Migraine
Advancing Patient Care in RA
Understanding and Addressing the Needs of Patients With AD
Advances in Severe Asthma Management
Battling the Flu: Latest Advances in the Influenza Treatment Arsenal
Guide to Atopic Dermatitis
Atopic Dermatitis in the Pediatric Practice
Defining the Clinical Value of Endpoints Used in Migraine Trials
EGPA.
Ask the Psoriasis Expert
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Patient Questions and Expert Answers in Psoriasis:
Severe Asthma and Comorbidities
Critical Decision Points in Insomnia
Update on the Management of Atopic Dermatitis
More Than Skin Deep.
Improving Overall Health
Peanut Allergy Immunotherapy
An Unmet Need.
Case Studies in Locally Advanced Pancreatic Cancer
Peanut Allergy Immunotherapy
Pathophysiologic Targets of Allergic Asthma
Patient and Clinician Perspectives on Preventive Therapy for Migraine
Monoclonal Antibodies in Migraine Prevention: What the Primary Care Physician Needs to Know.
Expert Perspectives.
Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults  Eric L. Simpson, MD, MCR,
Foundations of Asthma.
Late-Breaking Data on LDL-C Reduction
Psoriatic Arthritis.
Presentation transcript:

Translating Atopic Dermatitis

AD in Adults

Multidisciplinary Management of AD

AD Affects Overall Health

Patient Case Ethan

AD in Children

And the Guidelines Say…

Eczema Action Plans

Case Continued

Crisaborole Phase 3 Primary Efficacy Data

Crisaborole Phase 3 Secondary Efficacy Data

Crisaborole Phase 3 Safety Data

Targeted Agents for Mild-to-Moderate AD Phase 2 Trials

Dupilumab IL-4 Receptor mAb

Targeted Agents for Moderate-to-Severe AD Phase 2 Clinical Trials

Concluding Remarks

Abbreviations